Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

Impact · against what's priced in

Profound Medical gains a low-cost customer acquisition channel and a potential expansion of its addressable market through a strategic partnership with Telix. Telix benefits from increased visibility of its PSMA-PET imaging as a complementary tool for surgical planning, though the impact is more incremental for the larger radiopharmaceutical player.

PROF+0.60: No priced-in read yet

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

What matters in this story

TRexBio Announces Pricing of Initial Public Offering

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

What matters in this story

TRexBio Announces Pricing of Initial Public Offering

How each ticker is affected

Connected tickers

Track these names every morning.

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

What matters in this story

Next reads from the same story arc

TRexBio Announces Pricing of Initial Public Offering

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

What matters in this story

Next reads from the same story arc

TRexBio Announces Pricing of Initial Public Offering

How each ticker is affected

Connected tickers

Track these names every morning.

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.